Table 2. Stratification and interaction analyses for the association of rs12979860 genotype.
|
rs12979860(Fibrosis ≥2/fibrosis <2) |
Multiplicative interaction | ||||
|---|---|---|---|---|---|
| CC (n=1127) | CT/TT (n=2002) | OR (95% CI) | P-value* | P-value | |
| Age at time of biopsy (years) | |||||
| <40 | 230/228 | 207/508 | 2.47 (1.93–3.16) | 0.01 | 0.02 |
| ≥40 | 433/236 | 675/612 | 1.66 (1.37–2.01) | ||
| Sex | |||||
| Male | 416/322 | 620/622 | 1.29 (1.07–1.55) | 0.0002 | 0.01 |
| Female | 226/163 | 283/477 | 2.33 (1.82–2.99) | ||
| HCV genotype | |||||
| HCV-3 | 166/92 | 102/139 | 2.45 (1.71–3.52) | 0.009 | 0.1 |
| HCV-non 3 | 476/393 | 801/960 | 1.45 (1.23–1.7) | ||
| ALT | |||||
| <40 (IU l−1) | 126/152 | 234/416 | 1.47 (1.1–1.96) | 0.6 | 0.6 |
| ≥40 (IU l−1) | 516/333 | 669/683 | 1.58 (1.32–188) | ||
| ALT† | |||||
| <71 (IU l−1) | 245/256 | 426/736 | 1.65 (1.33–2.04) | 0.1 | 0.3 |
| ≥71 (IU l−1) | 397/229 | 477/363 | 1.32 (1.06–1.63) | ||
| Alcohol intake | |||||
| None or <50 g daily | 620/335 | 690/1038 | 2.78 (2.36–3.28) | 0.3 | 0.9 |
| ≥50 g daily | 112/60 | 123/151 | 2.29 (1.54–3.39) | ||
ALT, alanine aminotransferase; CI, confidence interval; OR, odds ratio.
Stratification and interaction analyses for the association of rs12979860 genotype, other clinical risk variables and liver fibrosis stage in the cohort of patients with chronic hepatitis C (n=3,129).
Data are as proportion by each category.
*P-value for differences between the OR for rs12979860 genotype within two strata of each clinical variable compared with each other. The OR are the result of univariate analysis. The interaction between the rs12979860 genotype and other clinical risk variables is quantified by the multiplicative measures of interaction.
†This stratification is based on median of ALT in the overall cohort.